[go: up one dir, main page]

PL2997033T3 - Skondensowane tricykliczne związki heterocykliczne jako inhibitory integrazy hiv - Google Patents

Skondensowane tricykliczne związki heterocykliczne jako inhibitory integrazy hiv

Info

Publication number
PL2997033T3
PL2997033T3 PL14798188T PL14798188T PL2997033T3 PL 2997033 T3 PL2997033 T3 PL 2997033T3 PL 14798188 T PL14798188 T PL 14798188T PL 14798188 T PL14798188 T PL 14798188T PL 2997033 T3 PL2997033 T3 PL 2997033T3
Authority
PL
Poland
Prior art keywords
heterocyclic compounds
hiv integrase
integrase inhibitors
tricyclic heterocyclic
fused tricyclic
Prior art date
Application number
PL14798188T
Other languages
English (en)
Inventor
Paul J. Coleman
Timothy J. Hartingh
Izzat T. Raheem
John Schreier
John T. Sisko
John Wai
Thomas Graham
Lihong Hu
Xuanjia Peng
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of PL2997033T3 publication Critical patent/PL2997033T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL14798188T 2013-05-17 2014-04-18 Skondensowane tricykliczne związki heterocykliczne jako inhibitory integrazy hiv PL2997033T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824739P 2013-05-17 2013-05-17
PCT/CN2014/075685 WO2014183532A1 (en) 2013-05-17 2014-04-18 Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP14798188.0A EP2997033B1 (en) 2013-05-17 2014-04-18 Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
PL2997033T3 true PL2997033T3 (pl) 2018-04-30

Family

ID=51897679

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14798188T PL2997033T3 (pl) 2013-05-17 2014-04-18 Skondensowane tricykliczne związki heterocykliczne jako inhibitory integrazy hiv

Country Status (19)

Country Link
US (1) US9643982B2 (pl)
EP (2) EP2997033B1 (pl)
AR (1) AR096332A1 (pl)
AU (1) AU2014267951A1 (pl)
CY (1) CY1119842T1 (pl)
DK (1) DK2997033T3 (pl)
ES (1) ES2656696T3 (pl)
HK (1) HK1248685A1 (pl)
HR (1) HRP20180081T1 (pl)
HU (1) HUE036384T2 (pl)
LT (1) LT2997033T (pl)
ME (1) ME02977B (pl)
NO (1) NO3058793T3 (pl)
PL (1) PL2997033T3 (pl)
PT (1) PT2997033T (pl)
RS (1) RS56701B1 (pl)
SI (1) SI2997033T1 (pl)
TW (1) TWI656122B (pl)
WO (1) WO2014183532A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3196201B1 (en) 2014-08-22 2021-04-28 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
TWI520963B (zh) * 2014-12-24 2016-02-11 國立清華大學 1,9-二氮萉衍生物及其製法
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
JP2020500866A (ja) * 2016-12-02 2020-01-16 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Hivインテグラーゼ阻害剤として有用な三環式複素環化合物
BR112020021768A2 (pt) * 2018-04-27 2021-01-26 Merck Sharp & Dohme Corp. compostos heterocíclicos tricíclicos úteis como inibidores de hiv-integrase
KR102770090B1 (ko) 2018-05-31 2025-02-18 시오노기 앤드 컴파니, 리미티드 다환성 피리돈 유도체
JP7328962B2 (ja) 2018-05-31 2023-08-17 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体
EP3801543B1 (en) 2018-06-05 2024-09-11 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
KR102564647B1 (ko) 2018-06-21 2023-08-11 에프. 호프만-라 로슈 아게 3-((1R,3R)-1-(2,6-다이플루오로-4-((1-(3-플루오로프로필)아제티딘-3-일)아미노)페닐)-3-메틸-1,3,4,9-테트라하이드로-2H-피리도[3,4-b]인돌-2-일)-2,2-다이플루오로프로판-1-올의 고체 형태, 치환된 페닐 또는 피리딘일 잔기를 포함하는 융합된 삼환형 화합물의 제조 방법, 및 이의 사용 방법
HUE059677T2 (hu) 2019-03-22 2022-12-28 Gilead Sciences Inc Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
JPWO2021107066A1 (pl) 2019-11-28 2021-06-03
CN115151545B (zh) 2020-02-24 2025-04-01 吉利德科学公司 用于治疗hiv感染的四环化合物
WO2022072520A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
CR20230315A (es) 2021-01-19 2023-09-01 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
ME00427B (me) 2001-10-26 2011-10-10 Msd Italia Srl N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
EP1441734B1 (en) 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
JP4523281B2 (ja) 2002-01-17 2010-08-11 メルク・シャープ・エンド・ドーム・コーポレイション Hivインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
JP4733986B2 (ja) 2002-12-27 2011-07-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー HIVインテグラーゼ阻害薬として有用なテトラヒドロ−4H−ピリド[1,2−a]ピリミジン類および関連する化合物
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
CN1930160B (zh) 2004-03-09 2011-11-16 默沙东公司 Hiv整合酶抑制剂
US7619086B2 (en) 2004-03-09 2009-11-17 Merck & Co., Inc. HIV integrase inhibitors
CA2557785A1 (en) * 2004-03-09 2005-10-06 Merck & Co. Inc. Hiv integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7981879B2 (en) 2005-03-31 2011-07-19 Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. HIV integrase inhibitors
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
WO2007059125A2 (en) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007143446A1 (en) 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
BR112012008586A2 (pt) 2009-10-13 2016-11-29 Elanco Animal Health Ireland inibidores da integrase macrocíclicos
CN102858771A (zh) * 2010-02-26 2013-01-02 日本烟草产业株式会社 1,3,4,8-四氢-2H-吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的用途
WO2011121105A1 (en) 2010-04-02 2011-10-06 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors

Also Published As

Publication number Publication date
WO2014183532A1 (en) 2014-11-20
LT2997033T (lt) 2018-02-12
TW201524978A (zh) 2015-07-01
NO3058793T3 (pl) 2018-03-17
EP3330272A1 (en) 2018-06-06
HRP20180081T1 (hr) 2018-02-23
HK1248685A1 (en) 2018-10-19
SI2997033T1 (en) 2018-04-30
US20160108059A1 (en) 2016-04-21
PT2997033T (pt) 2018-01-25
EP2997033A4 (en) 2016-10-26
US9643982B2 (en) 2017-05-09
AU2014267951A1 (en) 2015-11-19
DK2997033T3 (da) 2018-01-29
AR096332A1 (es) 2015-12-23
ME02977B (me) 2018-10-20
EP2997033B1 (en) 2017-11-15
CY1119842T1 (el) 2018-06-27
EP3330272B1 (en) 2021-02-17
HUE036384T2 (hu) 2018-07-30
EP2997033A1 (en) 2016-03-23
RS56701B1 (sr) 2018-03-30
ES2656696T3 (es) 2018-02-28
TWI656122B (zh) 2019-04-11

Similar Documents

Publication Publication Date Title
EP3008044A4 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
LT2997033T (lt) Kondensuoti tricikliniai heterocikliniai junginiai, kaip živ integrazės inhibitoriai
ZA201601708B (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors
IL246838A0 (en) A fused heterocyclic compound
IL239457A0 (en) Novel heterocyclic compounds as bromodomain inhibitors
EP3083641A4 (en) Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
IL266908A (en) Heterocyclic tetracyclic compounds for use as hiv integrase inhibitors
IL265496A (en) bace1 inhibitors
IL245301A0 (en) New heterocyclic compounds
ZA201508396B (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
IL245379A0 (en) Heterocyclic n-acylamino compounds
IL254424A0 (en) Disubstituted heterocyclic tricyclic compounds
ZA201508864B (en) Substituted heterocyclic compounds as crac modulators
IL240612A0 (en) Tricyclic heterocycles as anti-cancer agents
LT3063139T (lt) Heterociklinis junginys
IL244347A0 (en) n-acylamino heterocyclic compounds
IL241962B (en) Heterocyclic acetamide compound
GB201322752D0 (en) Novel ferrocenyl compounds
GB201314960D0 (en) Heterocyclic derivatives
GB201300306D0 (en) Heterocyclic derivatives
GB201300649D0 (en) Cyclization